Technology
Health
Pharmaceutical

Tetraphase Pharmaceuticals

$0.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0036 (-0.43%) Today
+$0.0249 (2.98%) After Hours

Why Robinhood?

You can buy or sell TTPH and other stocks, options, ETFs, and crypto commission-free!

About

Tetraphase Pharmaceuticals, Inc. Common Stock, also called Tetraphase Pharmaceuticals, is engaged in the development and production of novel antibiotics for serious and life-threatening bacterial infections. Read More It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Employees
119
Headquarters
Watertown, Massachusetts
Founded
2006
Market Cap
44.88M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
708.63K
High Today
$0.8613
Low Today
$0.7511
Open Price
$0.82
Volume
403.00K
52 Week High
$4.49
52 Week Low
$0.7511

Collections

Technology
Health
Pharmaceutical
2013 IPO
US
North America

News

Seeking AlphaMay 8

Tetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald on Q1 2019 Results - Earnings Call Transcript

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Jennifer Viera – Executive Director-Corporate Communications and Investor Relations Guy Macdonald – President and Chief Executive Officer Larry Edwards – Chief Operating Officer Larry Tsai – Chief Medical Officer Chris Watt – Senior Vice President-Finance Conference Call Participants Ted Tenthoff – Piper Jaffray Ellen Sands – Stifel Fang-Ke Huang – SunTrust Operator Good af...

394
NasdaqMay 8

Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates

144
Yahoo FinanceMay 2

Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, taking place May 8-11, 2019 in Orlando, Fla. Presentations will include data on XERAVATM (eravacycline), a novel, fully-synthetic fluorocycline, approved by the U.S. Food and...

229

Earnings

-$0.67
-$0.51
-$0.34
-$0.18
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.39 per share
Actual
-$0.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.